Compare Ascendis Pharma A/S (ASND) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Marsh & McLennan Companies, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Marsh & McLennan Companies, Inc. trades at $178.31 (market cap $85.91B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 4.8× Ascendis Pharma A/S's market cap, and Marsh & McLennan Companies, Inc. pays a 2.22% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MRSH | |
|---|---|---|
Market Cap | $17.74B | $85.91B |
Sector | Health | Financials |
52-Week High | $277.18 | $213.57 |
52-Week Low | $163.32 | $157.32 |
Enterprise Value | $18.11B | $106.75B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Marsh (MRSH) trades at $178.31, down 0.39% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.29 exceeding expectations, and recently raised its quarterly dividend by 10% to $0.99 per share. Revenue growth has been steady, reaching $26.98 billion in 2025, supported by a robust net income margin of 14.26%.
The outlook remains positive given consistent earnings outperformance and shareholder returns, though valuation multiples like a P/E of 22.29 and P/B of 5.9 suggest a premium. Risks include easing pricing tailwinds in insurance and rising costs. Analysts are predominantly neutral with a consensus price target of $199.44, indicating modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
